Browsing by Author "Onat, Ahmet Mesut"
Now showing items 1-3 of 3
-
Assessment of the New 2012 EULAR/ACR Clinical Classification Criteria for Polymyalgia Rheumatica: A Prospective Multicenter Study
Ozen, Gulsen; Inanc, Nevsun; Unal, Ali Ugur; Bas, Seda; Kimyon, Gezmis; Kisacik, Bunyamin; Onat, Ahmet Mesut; Murat, Sadiye; Keskin, Havva; Can, Meryem; Mengi, Alperen; Cakir, Necati; Balkarli, Ayse; Cobankara, Veli; Yilmaz, Neslihan; Yazici, Ayten; Dogru, Atalay; Sahin, Mehmet; Sahin, Ali; Gok, Kevser; Senel, Soner; Pamuk, Omer Nuri; Yilmaz, Sema; Bayindir, Ozun; Aksu, Kenan; Cagatay, Yonca; Akyol, Lutfi; Sayarlioglu, Mehmet; Yildirim-Cetin, Gozde; Yasar-Bilge, Sule; Yagci, Ilker; Aydin, Sibel Zehra; Alibaz-Oner, Fatma; Atagunduz, Pamir; Direskeneli, Haner (J RHEUMATOL PUBL CO, 2016)Objective. To assess the performance of the new 2012 provisional European League Against Rheumatism (EULAR)/ American College of Rheumatology (ACR) polymyalgia rheumatica (PMR) clinical classification criteria in discriminating ... -
Patients' concerns regarding biological agents in rheumatology
Pehlivan, Yavuz; Orucoglu, Nurdan; Pehlivan, Seda; Kimyon, Gezmis; Zengin, Orhan; Kucuk, Adem; Sahin, Ali; Tomas, Nazmiye; Oksuz, Mustafa Ferhat; Kisacik, Bunyamin; Akar, Servet; Onat, Ahmet Mesut; Dalkilic, Ediz (WILEY, 2018)ObjectiveThe potential side effects of biological agents may increase the anxiety levels of patients and influence not only their desire to use these therapies but also their concordance to treatment. This study aimed to ... -
Validation of New 2012 EULAR/ACR Classification Criteria for Polymyalgia Rheumatica: Comparison with the Previous Criteria in a Prospective Multi-Center Study
Ozen, Gulsen; Bas, Seda; Unal, Ali Ugur; Kimyon, Gezmis; Onat, Ahmet Mesut; Can, Meryem; Mengi, Alperen; Sahin, Ali; Yilmaz, Sema; Keskin, Havva; Murat, Sadiye; Balkarli, Ayse; Cobankara, Veli; Pamuk, Omer Nuri; Cagatay, Yonca; Yilmaz, Neslihan; Yagci, Ilker; Atagunduz, Pamir; Aydin, Sibel Z.; Inanc, Nevsun; Direskeneli, Haner (WILEY-BLACKWELL, 2014)…